| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
|
Kim, Jong Gwang
|
|
|
60 |
1 |
p. 129-134
|
artikel
|
| 2 |
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models
|
Zheng, Li-mou
|
|
|
60 |
1 |
p. 45-51
|
artikel
|
| 3 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
|
Tabata, Masahiro
|
|
|
60 |
1 |
p. 1-6
|
artikel
|
| 4 |
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
|
Krzyzanowska, Monika K.
|
|
|
60 |
1 |
p. 135-141
|
artikel
|
| 5 |
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
|
Cohen, Roger B.
|
|
|
60 |
1 |
p. 81-89
|
artikel
|
| 6 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study
|
Tabata, Masahiro
|
|
|
60 |
1 |
p. 53-59
|
artikel
|
| 7 |
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
|
Sève, Pascal
|
|
|
60 |
1 |
|
artikel
|
| 8 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
|
Binder, D.
|
|
|
60 |
1 |
p. 143-150
|
artikel
|
| 9 |
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin
|
Prijovich, Zeljko M.
|
|
|
60 |
1 |
p. 7-17
|
artikel
|
| 10 |
Inhibition of NF-κB-mediated transcription and induction of apoptosis by melampolides and repandolides
|
Ma, Guoyi
|
|
|
60 |
1 |
p. 35-43
|
artikel
|
| 11 |
Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line
|
Zastre, Jason
|
|
|
60 |
1 |
p. 91-102
|
artikel
|
| 12 |
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells
|
Wang, Chong-Zhi
|
|
|
60 |
1 |
p. 69-79
|
artikel
|
| 13 |
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer
|
Beinart, Garth A.
|
|
|
60 |
1 |
p. 61-67
|
artikel
|
| 14 |
The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line
|
Wu, Wei-Ciao
|
|
|
60 |
1 |
p. 103-111
|
artikel
|
| 15 |
The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
|
Triesscheijn, Martijn
|
|
|
60 |
1 |
p. 113-122
|
artikel
|
| 16 |
Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment
|
Mancinelli, Angelo
|
|
|
60 |
1 |
p. 19-26
|
artikel
|
| 17 |
Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer
|
Stathopoulos, G. P.
|
|
|
60 |
1 |
p. 123-128
|
artikel
|
Tijdschrift beschrijving